EP-1430: Venous thromboembolism in radiation oncology: retrospective trial

The potential “additive” thromboembolic risk of radiotherapy

“…Among 441 patients with lung cancer, 18 (4%) developed TE (13 venous and 5 arterial); median time to TE was 30 days (range 1-77). While TE incidence in this study (4%) was similar to the small prospective BIOTEL study (3%) and the previously described retrospective study of single modality radiotherapy (3-6%) 1 and lower than the 10-20% incidence reported among lung cancer patients receiving chemotherapy, findings should be confirmed in a larger prospective design.…”

“…We identified only one study evaluating TE among patients receiving single modality radiotherapy. 1 Other studies indiscriminately included patients receiving radiotherapy in conjunction with systemic therapies (Table 1). [2][3][4][5] In a prospective registry study, 13% (1202/9284) of patients who suffered TE in the setting of active cancer received radiotherapy.…”